Dr. John Wallace, Antibe Therapeutics Founder and Chief Science Officer, Awarded the Heymans Foundation Memorial Medal

Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) is proud to announce that Dr. John Wallace, the Corporation’s Founder and Chief Science Officer, was awarded the Heymans Foundation Memorial Medal in Ghent, Belgium, today. This prestigious award, named after Corneille Heymans, a 1938 Nobel Prize winner for Physiology/Medicine, has only been awarded 10 times since being established in 1972. Six of the previous winners were Nobel Laureates.

Dr. Wallace received this honour based on his studies of hydrogen sulfide as an endogenous anti-inflammatory, as well as the development of new medicines based on those findings, through Antibe Therapeutics.

For the last 20 years, Dr. Wallace's research has focused on gaining a better understanding of the ulcers that can arise from using painkillers and arthritis medications as well as of some the most common digestive disorders, including irritable bowel syndrome, ulcerative colitis, Crohn's disease, and colon cancer.

About Antibe Therapeutics Inc.

Antibe Therapeutics Inc. originates, develops and out-licenses patent-protected new pharmaceuticals that are improved versions of existing drugs. These improvements are based on Nobel Prize-winning medical research highlighting the crucial role of gaseous mediators, chemical substances produced in the human body to regulate a range of fundamental cellular processes. The Corporation’s drug design methodologies involve chemically linking an existing off-patent drug (“base drug”) to an Antibe-patented, hydrogen sulfide-releasing molecule. For medical conditions characterized by inflammation, pain or vascular dysfunction, the Corporation’s methodologies can efficiently produce improved versions of a number of existing drugs. Notably, Antibe’s products are themselves fully patent-protectable and may benefit from the predictable toxicity and effectiveness profiles of the base drug.

www.antibethera.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.